Injectable Drug Delivery Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global injectable drug delivery market growth forecasted to transform from USD 754.5 billion in 2024 to USD 1139.4 billion by 2029, driven by a CAGR of 8.6%. Growth of this market is mainly driven by increasing prevalence of Infectious diseases, Increasing technological advancements and increasing funding scenarios for R&D for the Injectable drug delivery market.

Injectable Drug Delivery Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Injectable Drug Delivery Market Dynamics

DRIVER: Increased Prevalence of Chronic Diseases

Injectable drug administration is critical for the treatment of a variety of infectious disorders, including bacterial, viral, fungal, and parasitic infections. Many antibiotics, antiviral treatments, antifungal agents, and antiparasitic therapies are supplied intravenously to achieve quick and effective drug concentrations in the bloodstream and target tissues.Injectable drugs are widely used to treat chronic infectious diseases such as tuberculosis (TB) and HIV/AIDS. To successfully target the TB germs and prevent medication resistance, TB treatment frequently combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin. Similarly, injectable antiretroviral medications can be used in HIV/AIDS therapy regimens to inhibit viral replication and slow disease progression.

RESTRAINT: Infections associated with needlestick injuries

Needlestick injuries, also known as percutaneous injuries, can transmit a variety of infectious pathogens if the needle or sharp instrument comes into contact with blood or bodily fluids. Other bloodborne infections that can be transmitted through needle injuries include syphilis, malaria, and human T-cell lymphotropic virus (HTLV). These infections can result in a variety of symptoms and problems, depending on the pathogen.

In addition to bloodborne pathogens, needlestick injuries can bring germs into the body, causing localized or systemic illness. Staphylococcus aureus, Streptococcus species, and gram-negative bacteria are among the most common bacterial illnesses associated with needlestick injuries.

OPPORTUNITY: Increase in demand for biosimilars and generic medicine

The need for biosimilars and generic injectable pharmaceuticals allows pharmaceutical companies to diversify their product portfolios in the injectable drug delivery sector. Companies can develop and manufacture a wide range of injectable biosimilars and generic pharmaceuticals for a variety of therapeutic areas, including oncology, autoimmune diseases, diabetes, and infectious diseases, to fulfill the growing demand for affordable and accessible treatments. Biosimilars and generic injectable drugs are less expensive and more affordable than brand-name medications, making them more accessible to individuals, healthcare providers, and healthcare systems. Injectable drug delivery systems are critical in the administration of biosimilars and generic pharmaceuticals, providing safe, effective, and easy delivery options for patients undergoing long-term or chronic therapies.

CHALLENGE: Preference for other modes of drug delivery

The injectable mode of drug delivery offers a large surface area for absorption as a result of which it achieves rapid systemic levels of absorption. However, the use of injectables can lead to needlestick injuries and infections, needle phobia, anxiety, and pain. All these factors limit the market for injectables to a certain extent. Among the various routes of drug delivery, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable.

Inhalation facilitates rapid absorption due to the huge surface area of the respiratory endothelium; bronchodilators and inhaled steroids can be targeted at the lungs with low levels of systemic absorption. The topical route of drug administration is considered better than injections as drugs are applied directly to the skin and it is non-invasive, easy, and there is a high level of patient compliance.

This preference for other routes of drug administration is a major challenge for the injectable drug delivery technology market.

Injectable Drug Delivery Market Ecosystem

The Formulations segment of the Injectable drug delivery industry is witnessed to have the highest growth during the forecast period.

Injectable formulations serve a wide range of therapeutic needs, including oncology, diabetes, autoimmune illnesses, cardiovascular disease, and infectious diseases. Each therapeutic category may necessitate unique formulations tailored to the drug's properties and the needs of the patient population, adding to the formulation segment's diversity. Continuous improvements in drug delivery technology enable the creation of novel formulations with improved features such as sustained release, targeted distribution, and increased stability. These developments fuel market expansion by increasing the number of injectable formulations available to healthcare practitioners and patients.

By Therapeutic application Infectious diseases segment of the Injectable drug delivery industry holds the largest share for 2023.

Vaccines are critical instruments for preventing infectious illnesses and mitigating their effects on public health. Injectable vaccinations are frequently used in immunization programs against a variety of infectious illnesses, including influenza, measles, polio, hepatitis, and human papillomavirus (HPV). The substantial percentage of injectable vaccinations in therapeutic applications is due to their development, manufacture, and dissemination.

Overall, the high share of infectious diseases in all therapeutic applications within the injectable drug market is due to the global burden of these diseases, the wide range of conditions they cover, the challenges posed by antimicrobial resistance, the prevalence of hospital-acquired infections, the impact of globalization and travel on disease spread, and the importance of vaccines in disease prevention and control.

By Route of Administration Skin/Intradermal accounted for the highest share of the Injectable drug delivery industry during the forecast period.

Compared to other delivery methods like intravenous or intramuscular injections, subcutaneous injections are comparatively easy to perform and don't require specific medical knowledge or equipment. In a variety of clinical settings, such as clinics, hospitals, and home healthcare settings, healthcare personnel can effortlessly provide subcutaneous injections. Drugs can be absorbed into the bloodstream more quickly and consistently in subcutaneous tissue because it has a robust blood supply and a comparatively large surface area. Because of this, subcutaneous injections are appropriate for drugs that need steady-state plasma concentrations because they enable predictable pharmacokinetics and dosage schedules.

To know about the assumptions considered for the study, download the pdf brochure

North America accounted for the largest share of the Injectable drug delivery industry in 2023.

Based on the region, the Injectable drug delivery market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the Injectable drug delivery market. This is due to an increase in the prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders. North America has one of the world's highest healthcare expenditures per capita. Significant investment in healthcare infrastructure, research, and pharmaceuticals helps to promote the widespread use of injectable drug delivery systems in the region.

Prominent players in the injectable drug delivery market are Becton, Dickinson and Company (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Baxter International, Inc. (U.S.), Sandoz (Germany), Terumo (Japan), Schott AG (Germany), Gerresheimer (Germany), Ypsomed (Switzerland), and B. Braun Melsungens (Germany).

Injectable Drug Delivery Market Report Scope

The study categorizes the injectable drug delivery market to forecast revenue and analyze trends in each of the following submarkets:

By Devices

• Conventional Injection Devices
• By material
  • Glass
  • Plastic
• By Product
  • Fillable Syringes
  • Prefilled Syringes
• By Usability
  • Reusable Injection Devices
  • Disposable Injection Devices
• Self-injection devices
• Needle-free Injectors
• By Product
  • Fillable Needle-free Injectors
  • Prefilled Needle-free Injectors
• By Technology
  • Jet-based Needle-free Injectors
  • Spring-based Needle-free Injectors
• Laser-powered needle free-injectors
  • Vibration-based Needle-free Injectors
• By Usability
  • Reusable needle-free Injectors
  • Disposable needle-free Injectors
• Autoinjectors
• By Product
  • Fillable Autoinjectors
  • Prefilled Autoinjectors
• By Technology
  • Automated Autoinjectors
  • Manual Autoinjectors
• By Design
  • Standardized Autoinjectors
  • Customized Autoinjectors
• By Usability
  • Reusable Autoinjectors
  • Disposable Autoinjectors
• Pen Injectors
• By Product
  • Single-chambered Pen Injectors
  • Dual-chambered Pen Injectors
• By Design
  • Standard Pen Injectors
  • Customized Pen Injectors
• By Usability
  • Reusable Pen Injectors
  • Disposable Pen Injectors
• Wearable Injectors
• Other Devices
• FORMULATIONS
• CONVENTIONAL DRUG DELIVERY FORMULATIONS
  • Solutions
  • Reconstituted/Lyophilized formulations
  • Suspensions
  • Emulsions
• NOVEL DRUG DELIVERY FORMULATIONS
  • Colloidal dispersions
  • Niosomes
  • Liposomes
  • Polymeric/mixed micelles
  • Nanoparticles
  • Solid-lipid nanoparticles
  • Nanosuspensions
  • Nanoemulsions
• MICROPARTICLES
  • Microspheres
  • Microcapsules
• LONG-ACTING INJECTION FORMULATIONS

By Formulation Packaging

• Introduction
• AMPOULES
• Vials
• Cartridges
• Bottles

By Therapeutic Application

• Introduction
• Autoimmune diseases
  • Rheumatoid arthritis
  • Multiple Sclerosis (MS)
  • Crohn’s Disease
  • Psoriasis
  • Other Autoimmune Diseases
• HORMONAL DISORDERS
  • Diabetes
  • Anemia
  • Reproductive health disease
  • Antithrombotic/thrombolytic therapy
  • Osteoporosis
  • growth hormone deficiency(GHD)
• Orphan diseases
• Cancer
• Infectious diseases
• Other therapeutic applications
  • Pain management
  • Allergies
  • Aesthetic treatment
  • Hepatitis C
  • Hemophilia

By Usage Pattern

• Introduction
• Curative care
• Immunization
• Others

By Site of Administration

• Introduction
• Skin(Intradermal and subcutaneous)
• Circulatory/Musculoskeletal system (Intravenous, Intracardiac, Intramuscular and Intraperitoneal)
• Organs (Intravitreal and Intra-articular)
• Central Nervous system ( Intracerebral and intrathecal)

By Distribution Channel

• Introduction
• Hospitals
• Retail Pharmacy stores

By Patient Care Setting

• Introduction
• Hospitals and Clinics
• Home care settings
• Other facilities of Use

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • RoE
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • RoAPAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • Rest of Middle East and Africa

Recent Developments of Injectable Drug Delivery Market

• In Sep 2022 BD launched BD EffivaxTM Glass prefillable syringes. This syringe will help in growing demand for vaccines manufacturing.
• In Oct 2022 GSK received its product approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) for immunization during the third trimester of pregnancy to help prevent pertussis (whooping cough) in infants younger than two months old.)
• In Nov 2023 Eli and Lilly received FDA approval for Zepbound injection which is the first and only obesity medication.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst